{"doi":"10.1002/alz.70793","title":"Multivariate models using NULISAseq and plasma p‐tau217 for staging Alzheimer's disease","abstract":"<jats:title>Abstract</jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION</jats:title>\n                    <jats:p>Plasma phospho‐tau217 (p‐tau217) has been shown to demonstrate equal performance to cerebrospinal fluid (CSF) to predict amyloid beta (Aβ) positivity. Although such high‐performing plasma tests provide confirmatory information on Aβ status, further information is desperately needed to discern optimal blood‐based biomarkers (BBMs) across the Alzheimer's disease (AD) stage.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS</jats:title>\n                    <jats:p>\n                      From the Australian Imaging, Biomarkers and Lifestyle study, 387 participants underwent [\n                      <jats:sup>18</jats:sup>\n                      F]NAV4694 (Aβ) and [\n                      <jats:sup>18</jats:sup>\n                      F]MK‐6240 (tau) PET scans, a blood test to measure for p‐tau217 (ALZpath and Lumipulse), and the Alamar Biosciences NULISASeq platform (120 central nervous system [CNS] and 250 inflammatory proteins). Individual p‐tau217 assays were compared with selected biomarker sets from the Alamar panel to predict AD stage.\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS</jats:title>\n                    <jats:p>Using a panel of biomarkers was significantly better at predicting disease stage compared with p‐tau217 alone; however, the difference was dependent upon p‐tau217 assay.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION</jats:title>\n                    <jats:p>Utility of extra BBMs in addition to p‐tau217 provides useful information regarding overall disease burden during the separate stages of AD.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights</jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Of the separate assays for p‐tau217, the Lumipulse assay demonstrated significantly better performance than the ALZpath assay to separate disease stages.</jats:p>\n                        </jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Multivariate blood‐based biomarker (BBM) models are significantly better at predicting the presence of A/T from A–T– as compared with any p‐tau217 assay.</jats:p>\n                        </jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Multivariate BBM models have higher area under the curve values to predict disease stage than Alamar and ALZpath p‐tau217, but not Lumipulse p‐tau217 during later disease stage comparisons.</jats:p>\n                        </jats:list-item>\n                      </jats:list>\n                    </jats:p>\n                  </jats:sec>","journal":"Alzheimer's &amp; Dementia","year":2025,"id":608539,"datarank":0.24141568686511508,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"self_citation_contribution":0.24141568686511508,"citation_network_contribution":0.0,"self_endowment_contribution":0.24141568686511508,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1563037,"name":"Edwin Stage","orcid":null,"position":1,"is_corresponding":false},{"id":236146,"name":"Christopher Fowler","orcid":"0000-0003-1397-0359","position":2,"is_corresponding":false},{"id":236166,"name":"Vincent Doré","orcid":"0000-0002-8051-0558","position":3,"is_corresponding":false},{"id":1563038,"name":"Nils Boehm","orcid":null,"position":4,"is_corresponding":false},{"id":1563039,"name":"Christoph Kleinert","orcid":null,"position":5,"is_corresponding":false},{"id":1177378,"name":"Malleswari Challagundla","orcid":null,"position":6,"is_corresponding":false},{"id":1075813,"name":"Azadeh Feizpour","orcid":"0000-0003-0826-4011","position":7,"is_corresponding":false},{"id":1563040,"name":"Larry Ward","orcid":null,"position":8,"is_corresponding":false},{"id":1563041,"name":"Jurgen Fripp","orcid":null,"position":9,"is_corresponding":false},{"id":219609,"name":"Colin L. Masters","orcid":null,"position":10,"is_corresponding":false},{"id":537562,"name":"Christopher Rowe","orcid":"0000-0002-2928-425X","position":11,"is_corresponding":false},{"id":1563042,"name":"Anthony Bannon","orcid":null,"position":12,"is_corresponding":false},{"id":236162,"name":"James D. Doecke","orcid":"0000-0003-2863-0293","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Multivariate models using NULISAseq and plasma p‐tau217 for staging Alzheimer's disease","abstract":"<jats:title>Abstract</jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION</jats:title>\n                    <jats:p>Plasma phospho‐tau217 (p‐tau217) has been shown to demonstrate equal performance to cerebrospinal fluid (CSF) to predict amyloid beta (Aβ) positivity. Although such high‐performing plasma tests provide confirmatory information on Aβ status, further information is desperately needed to discern optimal blood‐based biomarkers (BBMs) across the Alzheimer's disease (AD) stage.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS</jats:title>\n                    <jats:p>\n                      From the Australian Imaging, Biomarkers and Lifestyle study, 387 participants underwent [\n                      <jats:sup>18</jats:sup>\n                      F]NAV4694 (Aβ) and [\n                      <jats:sup>18</jats:sup>\n                      F]MK‐6240 (tau) PET scans, a blood test to measure for p‐tau217 (ALZpath and Lumipulse), and the Alamar Biosciences NULISASeq platform (120 central nervous system [CNS] and 250 inflammatory proteins). Individual p‐tau217 assays were compared with selected biomarker sets from the Alamar panel to predict AD stage.\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS</jats:title>\n                    <jats:p>Using a panel of biomarkers was significantly better at predicting disease stage compared with p‐tau217 alone; however, the difference was dependent upon p‐tau217 assay.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION</jats:title>\n                    <jats:p>Utility of extra BBMs in addition to p‐tau217 provides useful information regarding overall disease burden during the separate stages of AD.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights</jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Of the separate assays for p‐tau217, the Lumipulse assay demonstrated significantly better performance than the ALZpath assay to separate disease stages.</jats:p>\n                        </jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Multivariate blood‐based biomarker (BBM) models are significantly better at predicting the presence of A/T from A–T– as compared with any p‐tau217 assay.</jats:p>\n                        </jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Multivariate BBM models have higher area under the curve values to predict disease stage than Alamar and ALZpath p‐tau217, but not Lumipulse p‐tau217 during later disease stage comparisons.</jats:p>\n                        </jats:list-item>\n                      </jats:list>\n                    </jats:p>\n                  </jats:sec>","is_dataset_classified":null,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"41133401","pmcid":"PMC12550516","openalex_id":"https://openalex.org/W4415503519","authors":[],"funders":[{"funder_name":"Enigma Australia","grant_id":"","title":null},{"funder_name":"Eisai","grant_id":"","title":null},{"funder_name":"AbbVie","grant_id":"","title":null},{"funder_name":"Alzheimer&apos;s Drug Discovery Foundation","grant_id":"","title":null},{"funder_name":"Alzheimer's Association Australia","grant_id":"","title":null},{"funder_name":"Alzheimer's Drug Discovery Foundation","grant_id":"","title":null},{"funder_name":"Roche","grant_id":"","title":null},{"funder_name":"Bright Focus Foundation","grant_id":"","title":null},{"funder_name":"Medical Research Council","grant_id":"","title":null},{"funder_name":"Australian National Health","grant_id":"","title":null}],"total_grants":10,"fwci":3.3356,"citation_percentile":0.93124173,"influential_citations":0,"citation_trend":[{"year":2025,"count":2},{"year":2026,"count":2}],"oa_status":"hybrid","license":"cc-by-nc-nd","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.70793","host_type":"journal"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.70793","host_type":"publisher"},{"url":"https://alz-journals.onlinelibrary.wiley.com/doi/pdf/10.1002/alz.70793","host_type":"publisher"},{"url":"https://doi.org/10.1002/alz.70793","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/41133401","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/12550516","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC12550516","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC12550516?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Dementia and Cognitive Impairment Research","Alzheimer's disease research and treatments","Intracerebral and Subarachnoid Hemorrhage Research","Medicine"],"mesh_terms":["Aged","Aged, 80 and over","Alzheimer Disease","Australia","Female","Humans","Male","Biomarkers","Multivariate Analysis","Amyloid beta-Peptides","tau Proteins","Positron-Emission Tomography"],"keywords":["Multivariate statistics","Multivariate analysis","Disease","Biomarker","Prediction","Alzheimer's disease","Tau","Beta amyloid","Plasma Biomarker","Biological Staging"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T18:17:44.460420Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}